Is Cemiplimab an imported drug and its current status in the domestic supply chain and purchasing channels?

Cemiplimab (Cemiplimab) is an imported original monoclonal antibody immunotherapy drug. It was first approved by drug regulatory authorities in the United States and is used to treat a variety of cancer indications, such as locally advanced or metastatic cutaneous squamous cell carcinoma, non-small cell lung cancer, etc. Since the drug was developed by foreign pharmaceutical companies and mainly supplied in overseas markets, it has not yet entered the domestic market through formal drug marketing authorization, which also means that it has not yet established a regular medical supply chain in China.

Since the original drug Cemiplimab (Cemiplimab) has not yet been launched in China and is not covered by national medical insurance, domestic patients cannot directly purchase this drug in regular hospital pharmacies. Domestic cancer centers and hospitals currently mainly rely on other approved immune checkpoint inhibitors to carry out immunotherapy for related indications. Patients who wish to use cimepilimab need to pay attention to the approval progress of this drug in China and its future marketing trends.

In overseas markets, cimipri monoclonal antibody is already available in a common specification of 3 50mg/7mL (50mg/mL). Each box is sold for about RMB 40,000 to RMB 100,000 (the price may fluctuate due to exchange rate changes). The US version and the European version are currently the main sources of original research supply. If patients obtain it through legal cross-border medical services or self-funded introduction, they need to strictly abide by relevant laws and regulations to ensure that the source of the drug is formal, the transportation is compliant, and it is used under the guidance of a professional doctor.

There are currently no generic versions of cimepilimab on the market, so there are no lower-cost alternatives available. For patients who want early access to the drug, they can monitor its marketing application process in China and evaluate available treatment alternatives. During this period, if there is a need to introduce drugs from overseas, they must be handled through formal channels and legal procedures, and monitored by a professional medical team throughout the process to ensure drug safety and therapeutic effects.

Keyword tag:

PD-1Inhibitors, immunotherapy, cutaneous squamous cell carcinoma, non-small cell lung cancer, imported drugs, drug supply, expensive, no generic drugs, regular drug purchase channels

Reference materials:https://en.wikipedia.org/wiki/Cemiplimab